Table 2.
Baseline characteristics of the APPLE subjects.
| Variable | Mean (S.D.) or n (%) | Median | Total N |
|---|---|---|---|
| Age (years) | 15.7 (2.6) | 15.5 | 221 |
| Female | 184 (83.3%) | 221 | |
| Weight (kg) | 62.0 (17.2) | 58.7 | 221 |
| Body Mass Index | 24.4 (5.3) | 23.4 | 221 |
| Duration of Lupus (months) | 31.2 (28.5) | 25.0 | 220 |
| Hispanic | 54 (24.4%) | 221 | |
| Race*** | |||
| Caucasian | 114 (51.6%) | 221 | |
| African American | 59 (26.7%) | 221 | |
| Asian | 23 (10.4%) | 221 | |
| American Indian | 6 (2.7%) | 221 | |
| Native Hawaiian | 5 (2.3%) | 221 | |
| Other | 30 (13.6%) | 221 | |
| Minority (Hispanic Ethnicity or Non-Caucasian Race) | 144 (65.2%) | 221 | |
| Hx. Smoking (self-report) | 7 (3.2%) | 221 | |
| Prednisone Dose (mg/kg/day) | 0.19 (0.19) | 0.15 | 218 |
| Fam. Hx. Cardiovascular disease | 79 (37.4%) | 211 | |
| Creatinine Clearance (mL/min/m2) | 139.4 (33.0) | 134.1 | 216 |
| Proteinuria | 56 (25.5%) | 220 | |
| Hx. Renal Abnormalities | |||
| Hx. Hypertension | 73 (34.1%) | 214 | |
| Hx. Nephrotic syndrome | 38 (17.4%) | 219 | |
| Hx. Nephritis | 79 (36.1%) | 219 | |
| Other | 20 (10.5%) | 190 | |
| Current Medications | |||
| Hydroxychloroquine | 213 (96.4%) | 221 | |
| Corticosteroids | 181 (81.9%) | 221 | |
| Cyclophosphamide | 26 (11.8%) | 221 | |
| Mycophenolate | 53 (24.0%) | 221 | |
| Azathioprine | 30 (13.6%) | 221 | |
| Methotrexate | 29 (13.1%) | 221 | |
| ACE# inhibitors | 54 (24.4%) | 221 | |
| NSAIDs | 68 (30.8%) | 221 | |
| ASA | 147 (66.5%) | 221 | |
| Total Cholesterol (mg/dL) | 155.1 (38.0) | 148.0 | 211 |
| HDL Cholesterol (mg/dL) | 46.3 (12.8) | 44.0 | 211 |
| LDL Cholesterol (mg/dL) | 86.4 (31.4) | 78.5 | 210 |
| Triglycerides (mg/dL) | 114.0 (66.4) | 101.0 | 211 |
| Homocysteine (mcmol/L) | 7.5 (3.1) | 6.8 | 207 |
| Lp(a) (mg/dL) | 23.1 (26.8) | 13.5 | 206 |
| Log Lp(a) | 2.5 (1.2) | 2.6 | 206 |
| Mean-Maximal CIMT (mm) | 0.585 (0.052) | 0.579 | 221 |
| Mean-Mean Common CIMT (mm) | 0.468 (0.041) | 0.466 | 221 |
| HsCRP (mg/L) | 3.6 (13.9) | 0.7 | 202 |
| Log hsCRP | −0.27 (1.52) | −0.36 | 202 |
| ESR | 23.1 (22.9) | 16.0 | 148 |
| Anti-DS DNA antibody positive | 106 (48.0%) | 221 | |
| SLEDAI Total | 4.6 (4.2) | 4.0 | 221 |
| SLICC Damage Index >0 | 59 (26.7%) | 221 |
* Creatinine clearance calculated using Schwartz Formula as in methods
** Proteinuria defined as >500 mg/24 hours or spot protein:creatinine ratio of 0.5.
***
Some subjects self-reported more than one race.
#
Angiotensin converting enzyme